

SPECTRUM PHARMACEUTICALS, INC.

SCIENCE, TECHNOLOGY & SUSTAINABILITY COMMITTEE CHARTER

(Effective December 16, 2019)

The Purpose of the Science, Technology & Sustainability Committee

The primary purpose of the Science, Technology & Sustainability Committee (the “**Committee**”) of the Board of Directors (the “**Board**”) of Spectrum Pharmaceuticals, Inc. (the “**Company**”) is to assist the Board in:

- monitoring the state of science and technology capabilities within the Company and associated risks and the general oversight of the Company’s sustainability activities; and
- overseeing the development of key technologies and major science and medicine-driven innovation initiatives essential to the long-term success of the Company.

Membership and Structure

The Committee shall be comprised of at least three (3) directors, each of whom must (i) meet the director independence requirements set forth in the listing rules of The NASDAQ Stock Market in NASDAQ Listing Rule 5605(a)(2), (ii) be a “non-employee director” under Rule 16b-3 promulgated under the Securities Exchange Act of 1934, as amended, and (iii) be free from any relationship that, in the opinion of the Board, would interfere with the exercise of independent judgment as a member of the Committee. Appointment to the Committee, including the designation of the Chair of the Committee, shall be made by the Board. In determining whether a director is eligible to serve as a member of the Committee, the Board may consider the director’s scientific, regulatory, medical and technical expertise, as well as other relevant operational or business experience. The Board has the authority to remove members from the Committee in its sole discretion with or without cause. Any Committee member may resign effective upon giving oral or written notice to the Chair of the Committee, the Company’s Corporate Secretary or the Board (unless the notice specifies a later time for the effectiveness of such resignation). Vacancies occurring on the Committee shall be filled by the Board.

The Committee shall meet at least once per year and as often as necessary to carry out its duties at such times and places as the Committee shall determine, and shall also be able to take actions by written consent. Meetings may be held in person, telephonically or by video conferencing. When necessary, the Committee shall meet in executive session outside of the presence of any executive officer of the Company. The Chair of the Committee shall preside at each meeting (or, if absent, a designee member of the Committee) and shall report on activities of the Committee to the Board. A quorum of the Committee for the transaction of business will be a majority of its members. In fulfilling its responsibilities, the Committee shall have authority to delegate its authority to subcommittees, in each case to the extent permitted by applicable law.

Primary Responsibilities

The Committee shall:

- monitor and review the overall quality, competitiveness, strategy, direction and effectiveness of the Company's research and development;
- serve as a resource and provide input, as needed, regarding the scientific and technological aspects of product safety matters and efficacy of the product;
- identify and discuss new and emerging trends in pharmaceutical science, technology and regulation, and assure the Company makes well-informed choices in the investment of its research and development resources;
- regularly review the pipeline progress;
- assist the Company in minimizing its environmental impact through responsible practices;
- observe the evolution of science and medicine outside the Company, for possible application within the Company;
- assist the Board in identifying and comprehending significant emerging science and technology policy and public health issues and trends that may impact the Company's overall business strategy;
- assist the Board in its oversight of the Company's major acquisitions and business development activities as they relate to the acquisition or development of new science and technology; and
- review such other topics as are delegated to the Committee by the Board.

Additional Powers and Responsibilities

In addition to the specific responsibilities set forth above, the Committee will:

- engage in an annual self-assessment with the goal of continuing improvement;
- annually review and reassess the adequacy of this Charter, and recommend any changes to the Board;
- report regularly to the Board on its meetings and review with the Board significant issues and concerns that arise at Committee meetings;
- have authority and appropriate funds to retain, consult with and compensate outside counsel and other advisors as the Committee may deem appropriate;
- have the authority to invite to its meetings, or to meet with any members of or advisers to the Committee, members of management or other experts whose presence is deemed desirable and appropriate;
- have unrestricted access to Company personnel and documents, and have authority to direct and supervise an investigation into any matters within the scope of its duties;

- have sole authority to approve the ordinary administrative expenses of the Committee that are necessary or appropriate for carrying out its duties; and
- perform other activities required by applicable laws, rules, regulations or listing requirements applicable to the Company.

In addition to the powers and responsibilities expressly delegated to the Committee in this Charter, the Committee may exercise any other powers and carry out any other responsibilities delegated to it by the Board from time to time consistent with the Company's bylaws and Certificate of Incorporation. The powers and responsibilities delegated by the Board to the Committee in this Charter or otherwise shall be exercised and carried out by the Committee as it deems appropriate without requirement of Board approval, and any decision made by the Committee shall be at the Committee's sole discretion. With respect to any authority or responsibilities granted to the Committee by this Charter, in lieu of making a final determination with respect thereto, the Committee may make a recommendation to the Board for its final approval thereof. Nothing in this Charter is intended to preclude or impair the protection provided in Section 141(e) of the Delaware General Corporation Law for good faith reliance by members of the Committee on reports or other information provided by others.